FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107562280> ?p ?o ?g. }

• W2107562280 abstract "Pouchitis occurs in approximately 50% of patients following ileal pouch-anal anastomosis (IPAA) for chronic ulcerative colitis.The primary objective was to determine the efficacy and safety of medical therapies (including antibiotics, probiotics, and other agents) for prevention or treatment of acute or chronic pouchitis.We searched MEDLINE, EMBASE and the Cochrane Library from inception to October 2014.Randomized controlled trials of prevention or treatment of acute or chronic pouchitis in adults who underwent IPAA for ulcerative colitis were considered for inclusion.Two authors independently screened studies for eligibility, extracted data and assessed study quality. Methodological quality was assessed using the Cochrane risk of bias tool. The overall quality of the evidence supporting the outcomes was evaluated using the GRADE criteria. The primary outcome was the proportion of patients with clinical improvement or remission of pouchitis in patients with acute or chronic pouchitis, or the proportion of patients with no episodes of pouchitis after IPAA. The proportion of patients who developed at least one adverse event was a secondary outcome. We calculated the risk ratio (RR) and corresponding 95% confidence interval (CI) for each dichotomous outcome.Thirteen studies (517 participants) were included in the review. Four studies assessed treatment of acute pouchitis. One study (16 participants) compared ciprofloxacin and metronidazole; another (26 participants) compared metronidazole to budesonide enemas; another (18 participants) compared rifaximin to placebo; and the fourth study (20 participants) compared Lactobacillus GG to placebo. Four studies assessed treatment of chronic pouchitis. One study (19 participants) compared glutamine to butyrate suppositories; another (40 participants) compared bismuth enemas to placebo; and two studies (76 participants) compared VSL#3 to placebo. Five studies assessed prevention of pouchitis. One study (40 participants) compared VSL#3 to placebo; another (28 participants) compared VLS#3 to no treatment; one study (184 participants) compared allopurinol to placebo; another (12 participants) compared the probiotic Bifidobacterium longum to placebo; and one study (38 participants) compared tinidazole to placebo. Three studies were judged to be of high quality. Two studies were judged to be low quality and the quality of the other studies was unclear. Treatment of acute pouchitis: The results of one small study (16 participants) suggest that ciprofloxacin may be more effective than metronidazole for the treatment of acute pouchitis. One hundred per cent (7/7) of ciprofloxacin patients achieved remission at two weeks compared to 33% (3/9) of metronidazole patients. A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due to high risk of bias (no blinding) and very sparse data (10 events). There was no difference in the proportion of patients who had at least one adverse event (RR 0.18, 95% CI 0.01 to 2.98). Adverse events included vomiting, dysgeusia or transient peripheral neuropathy. There were no differences between metronidazole and budesonide enemas in terms of clinical remission, clinical improvement or adverse events. Adverse events included anorexia, nausea, headache, asthenia, metallic taste, vomiting, paraesthesia, and depression. There were no differences between rifaximin and placebo in terms of clinical remission, clinical improvement, or adverse events. Adverse events included diarrhea, flatulence, nausea, proctalgia, vomiting, thirst, candida, upper respiratory tract infection, increased hepatic enzyme, and cluster headache. There was no difference in clinical improvement between Lactobacillus GG and placebo. The results of these studies are uncertain due to very low quality evidence. Treatment of chronic pouchitis: A pooled analysis of two studies (76 participants) suggests that VSL#3 may be more effective than placebo for maintenance of remission. Eighty-five per cent (34/40) of VLS#3 patients maintained remission at 9 to 12 months compared to 3% (1/36) of placebo patients (RR 20.24, 95% CI 4.28 to 95.81). A GRADE analysis indicated that the quality of evidence supporting this outcome was low due to very sparse data (35 events). Adverse events included abdominal cramps, vomiting and diarrhea. There was no difference in effectiveness between glutamine and butyrate suppositories for maintenance of remission. There was no difference in clinical improvement or adverse event rates between bismuth carbomer foam enemas and placebo. Adverse events included diarrhea, worsening symptoms, cramping, sinusitis, and abdominal pain. The results of these studies are uncertain due to very low quality evidence. Prevention of pouchitis: The results of one small study (40 participants) suggest that VSL#3 may be more effective than placebo for prevention of pouchitis. Ninety per cent (18/20) of VSL#3 patients had no episodes of acute pouchitis during the 12 month study compared to 60% (12/20) of placebo patients (RR 1.50, 95% CI 1.02 to 2.21). A GRADE analysis indicated that the quality of evidence supporting this outcome was low due to very sparse data (30 events). Another small study (28 participants) found that VLS#3 was not more effective than no treatment for prevention of pouchitis. Bifidobacterium longum, allopurinol and tinidazole were not more effective than placebo for prevention of pouchitis. The results of these studies are uncertain due to very low quality evidence.For acute pouchitis, very low quality evidence suggests that ciprofloxacin may be more effective than metronidazole. For chronic pouchitis, low quality evidence suggests that VSL#3 may be more effective than placebo for maintenance of remission. For the prevention of pouchitis, low quality evidence suggests that VSL#3 may be more effective than placebo. Well designed, adequately powered studies are needed to determine the optimal therapy for the treatment and prevention of pouchitis." @default.
• W2107562280 created "2016-06-24" @default.
• W2107562280 creator A5016245381 @default.
• W2107562280 creator A5032150391 @default.
• W2107562280 creator A5035847062 @default.
• W2107562280 creator A5041424641 @default.
• W2107562280 creator A5081432241 @default.
• W2107562280 date "2015-11-23" @default.
• W2107562280 modified "2023-10-16" @default.
• W2107562280 title "Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis" @default.
• W2107562280 cites W1569233009 @default.
• W2107562280 cites W1696136056 @default.
• W2107562280 cites W1810584900 @default.
• W2107562280 cites W1951257337 @default.
• W2107562280 cites W1953831249 @default.
• W2107562280 cites W1973691341 @default.
• W2107562280 cites W1974707545 @default.
• W2107562280 cites W1982760743 @default.
• W2107562280 cites W1982889834 @default.
• W2107562280 cites W1989132981 @default.
• W2107562280 cites W1995508220 @default.
• W2107562280 cites W2001371419 @default.
• W2107562280 cites W2002355035 @default.
• W2107562280 cites W2007838388 @default.
• W2107562280 cites W2012138234 @default.
• W2107562280 cites W2032022835 @default.
• W2107562280 cites W2037111559 @default.
• W2107562280 cites W2039593249 @default.
• W2107562280 cites W2051263773 @default.
• W2107562280 cites W2058440611 @default.
• W2107562280 cites W2058616057 @default.
• W2107562280 cites W2061423487 @default.
• W2107562280 cites W2063512218 @default.
• W2107562280 cites W2066551697 @default.
• W2107562280 cites W2068497688 @default.
• W2107562280 cites W2072552500 @default.
• W2107562280 cites W2083513339 @default.
• W2107562280 cites W2087250562 @default.
• W2107562280 cites W2090853704 @default.
• W2107562280 cites W2091250795 @default.
• W2107562280 cites W2094682242 @default.
• W2107562280 cites W2101533048 @default.
• W2107562280 cites W2115778673 @default.
• W2107562280 cites W2130049028 @default.
• W2107562280 cites W2139387284 @default.
• W2107562280 cites W2143147290 @default.
• W2107562280 cites W2149993196 @default.
• W2107562280 cites W2153551892 @default.
• W2107562280 cites W2155703794 @default.
• W2107562280 cites W2156680557 @default.
• W2107562280 cites W2157687589 @default.
• W2107562280 cites W2160610633 @default.
• W2107562280 cites W2161693745 @default.
• W2107562280 cites W2165010366 @default.
• W2107562280 cites W2325219982 @default.
• W2107562280 cites W2405550176 @default.
• W2107562280 cites W4235500728 @default.
• W2107562280 cites W4241852057 @default.
• W2107562280 cites W4251870332 @default.
• W2107562280 cites W4252274934 @default.
• W2107562280 cites W4252742165 @default.
• W2107562280 cites W2056486174 @default.
• W2107562280 doi "https://doi.org/10.1002/14651858.cd001176.pub3" @default.
• W2107562280 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6885001" @default.
• W2107562280 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31785173" @default.
• W2107562280 hasPublicationYear "2015" @default.
• W2107562280 type Work @default.
• W2107562280 sameAs 2107562280 @default.
• W2107562280 citedByCount "106" @default.
• W2107562280 countsByYear W21075622802012 @default.
• W2107562280 countsByYear W21075622802013 @default.
• W2107562280 countsByYear W21075622802014 @default.
• W2107562280 countsByYear W21075622802015 @default.
• W2107562280 countsByYear W21075622802016 @default.
• W2107562280 countsByYear W21075622802017 @default.
• W2107562280 countsByYear W21075622802018 @default.
• W2107562280 countsByYear W21075622802019 @default.
• W2107562280 countsByYear W21075622802020 @default.
• W2107562280 countsByYear W21075622802021 @default.
• W2107562280 countsByYear W21075622802022 @default.
• W2107562280 countsByYear W21075622802023 @default.
• W2107562280 crossrefType "journal-article" @default.
• W2107562280 hasAuthorship W2107562280A5016245381 @default.
• W2107562280 hasAuthorship W2107562280A5032150391 @default.
• W2107562280 hasAuthorship W2107562280A5035847062 @default.
• W2107562280 hasAuthorship W2107562280A5041424641 @default.
• W2107562280 hasAuthorship W2107562280A5081432241 @default.
• W2107562280 hasBestOaLocation W21075622801 @default.
• W2107562280 hasConcept C126322002 @default.
• W2107562280 hasConcept C142724271 @default.
• W2107562280 hasConcept C168563851 @default.
• W2107562280 hasConcept C204787440 @default.
• W2107562280 hasConcept C27081682 @default.
• W2107562280 hasConcept C2777396551 @default.
• W2107562280 hasConcept C2778889925 @default.
• W2107562280 hasConcept C2779134260 @default.
• W2107562280 hasConcept C2779454807 @default.
• W2107562280 hasConcept C2780479503 @default.
• W2107562280 hasConcept C2780615123 @default.
• W2107562280 hasConcept C501593827 @default.

• next